The myocardial area at risk

Sudden occlusion of a coronary artery initiates an expanding array of functional, metabolic and structural abnormalities, ultimately leading to myocyte necrosis, which extends from the subendocardial to the subepicardial layers of the perfusion bed—what Reimer called the ‘wavefront phenomenon’.1 In this setting, the myocardial area at risk (AAR) is defined as the myocardial tissue within the vascular territory that is distal to the culprit lesion of the infarct-related artery. If not timely reperfused, this area is at definite risk of ischaemic death. In humans, the portion of the AAR, that is irreversibly injured (ie, infarcted) ranges from 0% (aborted infarction) to as much as 88%.2 The proportion of the AAR that ultimately survives—that is, the salvaged myocardium—is dependent on multiple factors, including time to reperfusion, ischaemic preconditioning, collateral flow, distal embolisation, reperfusion injury and microvascular dysfunction. Since the extent of myocardial salvage is an important determinant of final infarct size, the quantitative assessment of myocardial salvage offers tremendous potential to aid in the development of novel therapeutic strategies targeted at reducing ischaemic/reperfusion injury in the setting of acute myocardial infarction (MI). The extent of myocardial salvage is defined as the difference between the total AAR and final infarct size. Therefore, in recent years there has been a renewed interest in techniques used for the assessment of the myocardial AAR in patients with acute MI. However, in contrast to myocardial delayed enhancement MRI (MDE-MRI), which represents a robust and validated technique that allows for an accurate assessment and detailed characterisation of the infarcted regions,3 quantification of the AAR still remains challenging. In animal studies, fluorescein staining and fluorescent microspheres are the reference standard for measuring the AAR.4–6 In humans, a commonly used technique is single-photon emission tomography, which requires …

[1]  N. Keating,et al.  Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. , 2012, Journal of the National Cancer Institute.

[2]  R. Kim,et al.  Performance of angiographic, electrocardiographic and MRI methods to assess the area at risk in acute myocardial infarction , 2011, Heart.

[3]  R. Kim,et al.  T2-weighted imaging to assess post-infarct myocardium at risk. , 2011, JACC. Cardiovascular imaging.

[4]  G. Schuler,et al.  Myocardium at risk in ST-segment elevation myocardial infarction comparison of T2-weighted edema imaging with the MR-assessed endocardial surface area and validation against angiographic scoring. , 2011, JACC. Cardiovascular imaging.

[5]  N. Tanaka,et al.  The effects of androgen deprivation therapy on lipid metabolism and body composition in Japanese patients with prostate cancer. , 2011, Japanese journal of clinical oncology.

[6]  P. Walsh Re: Statin Medication Use and the Risk of Biochemical Recurrence After Radical Prostatectomy: Results From the Shared Equal Access Regional Cancer Hospital (SEARCH) Database , 2011 .

[7]  Stacey A. Kenfield,et al.  Physical activity and survival after prostate cancer diagnosis in the health professionals follow-up study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  H. Doll,et al.  Lifestyle Intervention in Men with Advanced Prostate Cancer Receiving Androgen Suppression Therapy: A Feasibility Study , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[9]  A. Kibel Combined Resistance and Aerobic Exercise Program Reverses Muscle Loss in Men Undergoing Androgen Suppression Therapy for Prostate Cancer Without Bone Metastases: A Randomized Controlled Trial , 2010 .

[10]  J. Kaufman,et al.  Endogenous testosterone and cardiovascular disease in healthy men: a meta-analysis , 2010, Heart.

[11]  A. D'Amico Is long-term androgen suppression right for everyone with locally advanced prostate cancer? , 2010, The Lancet. Oncology.

[12]  C. L. Cutajar,et al.  External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. , 2010, The Lancet. Oncology.

[13]  P. Morris,et al.  Low serum testosterone and increased mortality in men with coronary heart disease , 2010, Heart.

[14]  P. Kellman,et al.  Magnetic Resonance Imaging Delineates the Ischemic Area at Risk and Myocardial Salvage in Patients With Acute Myocardial Infarction , 2010, Circulation. Cardiovascular imaging.

[15]  Mats Lambe,et al.  Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe Sweden. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  A. D'Amico,et al.  Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. , 2010, Circulation.

[17]  C. Lawton Cardiovascular Mortality After Androgen Deprivation Therapy for Locally Advanced Prostate Cancer: RTOG 85-31 , 2010 .

[18]  A. Meikle Low circulating androgens and mortality risk in heart failure , 2010 .

[19]  C. Lawton Impact of the Duration of Adjuvant Hormonal Therapy in Patients With Locally Advanced Prostate Cancer Treated With Radiotherapy: A Secondary Analysis of RTOG 85-31 , 2010 .

[20]  A. D'Amico,et al.  Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. , 2009, JAMA.

[21]  S. Dymarkowski,et al.  Quantification of myocardial area at risk with T2-weighted CMR: comparison with contrast-enhanced CMR and coronary angiography. , 2009, JACC. Cardiovascular imaging.

[22]  J. Schulz-Menger,et al.  The salvaged area at risk in reperfused acute myocardial infarction as visualized by cardiovascular magnetic resonance. , 2008, Journal of the American College of Cardiology.

[23]  D. Nathan,et al.  Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer. , 2008, Urology.

[24]  Andrew E Arai,et al.  In Vivo T2-Weighted Magnetic Resonance Imaging Can Accurately Determine the Ischemic Area at Risk for 2-Day-Old Nonreperfused Myocardial Infarction , 2008, Investigative radiology.

[25]  I. Derweesh,et al.  Risk of new‐onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen‐deprivation therapy for prostate cancer , 2007, BJU international.

[26]  Daniel C. Lee,et al.  Angiographic estimates of myocardium at risk during acute myocardial infarction: validation study using cardiac magnetic resonance imaging. , 2007, European heart journal.

[27]  A. D'Amico,et al.  Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  A. Dobs,et al.  Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  R. F. Hoyt,et al.  Cardiac magnetic resonance imaging , 2004, Postgraduate Medical Journal.

[30]  D. Nathan,et al.  Insulin sensitivity during combined androgen blockade for prostate cancer. , 2006, The Journal of clinical endocrinology and metabolism.

[31]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[32]  A. Lenzi,et al.  Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle‐aged men: a meta‐analysis , 2005, Clinical endocrinology.

[33]  Fernando Costa,et al.  Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Ph , 2003, Circulation.

[34]  C. Bulpitt,et al.  Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. , 2003, Clinical science.

[35]  P. Nguyen,et al.  Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma , 2002, Cancer.

[36]  O. Simonetti,et al.  Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. , 1999, Circulation.

[37]  J. Gili,et al.  Analysis of myocardial oedema by magnetic resonance imaging early after coronary artery occlusion with or without reperfusion. , 1993, Cardiovascular research.

[38]  J L Duerk,et al.  Distinguishing viable from infarcted myocardium after experimental ischemia and reperfusion by using nuclear magnetic resonance imaging. , 1990, Journal of the American College of Cardiology.

[39]  T J Brady,et al.  Effect of hyperosmotic mannitol on magnetic resonance relaxation parameters in reperfused canine myocardial infarction. , 1989, Magnetic resonance imaging.

[40]  B R Rosen,et al.  Assessment of myocardial ischemia with proton magnetic resonance: effects of a three hour coronary occlusion with and without reperfusion. , 1985, Circulation.

[41]  E S Kirk,et al.  The Microcirculation of the Human Heart: End‐capillary Loops with Discrete Perfusion Fields , 1982, Circulation.

[42]  R E Ideker,et al.  Myocardial Infarct Size and Location in Relation to the Coronary Vascular Bed at Risk in Man , 1981, Circulation.

[43]  Reimer Ka,et al.  The "wavefront phenomenon" of myocardial ischemic cell death. II. Transmural progression of necrosis within the framework of ischemic bed size (myocardium at risk) and collateral flow. , 1979 .

[44]  R. Jennings,et al.  The "wavefront phenomenon" of myocardial ischemic cell death. II. Transmural progression of necrosis within the framework of ischemic bed size (myocardium at risk) and collateral flow. , 1979, Laboratory investigation; a journal of technical methods and pathology.